Developer docs
API playgroundTry for free, no card

Search company profiles

Micropharma

Full company profile

uuid000fbdd

Namestring
Micropharma
Websiteurl
micropharma.net
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Micropharma is a privately held Canadian biotechnology company founded in 2004 and headquartered in Montréal, Quebec. According to firmographic data, the company develops biotherapeutics, diagnostics, and medical devices targeting metabolic diseases, and operates with a small team of 11–50 employees. The entity is described as operating, with no public ticker and no disclosed parent company or subsidiaries.

The company's only disclosed capital event is a single funding round of approximately $851,242 closed on January 24, 2013, with unknown investors and no identified lead. Leadership comprises CEO Ryan Jones, founder and co-founder Satya Prakash, and director Robert Semmens. No patents, trademarks, products, services, partnerships, regulatory actions, or AI/ML capabilities are disclosed in the available source data.

The current website at micropharma.net displays Japanese-language WordPress blog content on nursing workplace confidence topics, which is materially inconsistent with the firmographic description of a metabolic-disease biotech. This anomaly — between a Montréal biotech profile and a Japanese-language nursing content blog — suggests either a domain lapse and repurchase, a pivot, or a data-aggregation error in the firmographic feed. No recent operating milestones, product launches, or commercial activity are disclosed.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMontréal, Canada
HQ citystring
Montréal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biotherapeutics development, metabolic disease therapeutics, diagnostic device development, pharmaceutical product development, biotech research services
Industry3 codes
PRIMARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
Product category
Biopharmaceuticals
Social media profiles1 record
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Micropharma develops biotherapeutics, diagnostics, and medical devices targeted at metabolic diseases. The company operates as a small private biopharmaceutical and medical device firm headquartered in Montréal, Canada, with 11-50 employees, focused on therapeutic, diagnostic, and device product development for metabolic conditions.

Differentiator
Functional benefit
Problem solved
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage developer of engineered microbiome-based biotherapeutics for metabolic and inflammatory diseases. Directly comparable to Micropharma's stated biotherapeutics-for-metabolic-disease positioning.

TypeDirect peer
Description

Develops defined-consortium live biotherapeutic products for metabolic, autoimmune, and infectious diseases. Closely aligned with Micropharma's claimed engineered microbial therapeutic platform.

3Novome Biotechnologies
TypeDirect peer
Description

Engineered microbial therapeutics company focused on metabolic diseases including hyperoxaluria. Shares Micropharma's biotherapeutic-plus-metabolic-disease niche.

4Second Genome
TypeDirect peer
Description

Microbiome-based therapeutic developer using synthetic biology approaches to target metabolic and inflammatory conditions. Comparable in modality and disease focus.

TypeDirect peer
Description

Develops microbiome-derived small molecules and engineered microbial candidates for metabolic and immune-mediated diseases. Directly comparable biotherapeutic platform.

TypeDirect peer
Description

Microbiome therapeutics company developing whole-microbiome and engineered consortia products for metabolic and gastrointestinal indications.

7Kaleido Biosciences
TypeEmerging player
Description

Targeted microbe-derived and synthetic biology-based interventions for metabolic and inflammatory diseases. Closely comparable to Micropharma's stated pipeline direction.

TypeEmerging player
Description

Small-molecule and biologic developer with programs in metabolic and cancer indications; comparable as a small-cap biotherapeutic developer pursuing metabolic diseases.

TypeDirect peer
Description

Swedish microbiome-derived biotherapeutics company focused on metabolic and liver diseases. Direct overlap in therapeutic area and microbial therapeutic modality.

10BioGaia
TypeBroad incumbent
Description

Established probiotics and microbiome-based product company with metabolic and gastrointestinal health products. Comparable as a broader microbiome health/biotherapeutic platform.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Micropharma

Biopharmaceuticalsmicropharma.net

What Micropharma does

Micropharma is a privately held Canadian biotechnology company founded in 2004 and headquartered in Montréal, Quebec. According to firmographic data, the company develops biotherapeutics, diagnostics, and medical devices targeting metabolic diseases, and operates with a small team of 11–50 employees. The entity is described as operating, with no public ticker and no disclosed parent company or subsidiaries.

The company's only disclosed capital event is a single funding round of approximately $851,242 closed on January 24, 2013, with unknown investors and no identified lead. Leadership comprises CEO Ryan Jones, founder and co-founder Satya Prakash, and director Robert Semmens. No patents, trademarks, products, services, partnerships, regulatory actions, or AI/ML capabilities are disclosed in the available source data.

The current website at micropharma.net displays Japanese-language WordPress blog content on nursing workplace confidence topics, which is materially inconsistent with the firmographic description of a metabolic-disease biotech. This anomaly — between a Montréal biotech profile and a Japanese-language nursing content blog — suggests either a domain lapse and repurchase, a pivot, or a data-aggregation error in the firmographic feed. No recent operating milestones, product launches, or commercial activity are disclosed.

Micropharma firmographics

Firmographics
Name
Micropharma
Website
https://micropharma.net
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Micropharma industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)

Keywords

  • Biotherapeutics development
  • Metabolic disease therapeutics
  • Diagnostic device development
  • Pharmaceutical product development
  • Biotech research services

Where Micropharma is headquartered

Location

Headquarters

HQ city
Montréal
HQ country
Canada
HQ region
North America

Markets served

Micropharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Marketing channels1 record

Micropharma product offering

Product offering

Core offering

Micropharma develops biotherapeutics, diagnostics, and medical devices targeted at metabolic diseases. The company operates as a small private biopharmaceutical and medical device firm headquartered in Montréal, Canada, with 11-50 employees, focused on therapeutic, diagnostic, and device product development for metabolic conditions.

Differentiator

Problem solved

Functional benefit

Companies that use Micropharma

Customer profile

Segments1 record

Ideal customer profiles1 record

Micropharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Micropharma partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights1 record

Micropharma competitors and assessment

Company assessment

Direct peers

  • Seres Therapeutics: Clinical-stage developer of engineered microbiome-based biotherapeutics for metabolic and inflammatory diseases. Directly comparable to Micropharma's stated biotherapeutics-for-metabolic-disease positioning.
  • Vedanta Biosciences: Develops defined-consortium live biotherapeutic products for metabolic, autoimmune, and infectious diseases. Closely aligned with Micropharma's claimed engineered microbial therapeutic platform.
  • Novome Biotechnologies: Engineered microbial therapeutics company focused on metabolic diseases including hyperoxaluria. Shares Micropharma's biotherapeutic-plus-metabolic-disease niche.
  • Second Genome: Microbiome-based therapeutic developer using synthetic biology approaches to target metabolic and inflammatory conditions. Comparable in modality and disease focus.
  • Enterome: Develops microbiome-derived small molecules and engineered microbial candidates for metabolic and immune-mediated diseases. Directly comparable biotherapeutic platform.
  • Finch Therapeutics: Microbiome therapeutics company developing whole-microbiome and engineered consortia products for metabolic and gastrointestinal indications.
  • MetaboGen: Swedish microbiome-derived biotherapeutics company focused on metabolic and liver diseases. Direct overlap in therapeutic area and microbial therapeutic modality.

Emerging players

  • Kaleido Biosciences: Targeted microbe-derived and synthetic biology-based interventions for metabolic and inflammatory diseases. Closely comparable to Micropharma's stated pipeline direction.
  • Aprea Therapeutics: Small-molecule and biologic developer with programs in metabolic and cancer indications; comparable as a small-cap biotherapeutic developer pursuing metabolic diseases.

Broad incumbents

  • BioGaia: Established probiotics and microbiome-based product company with metabolic and gastrointestinal health products. Comparable as a broader microbiome health/biotherapeutic platform.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights3 records

Customer concentration

Micropharma social profiles

Digital presence

Micropharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Micropharma leadership team

Management profile

Number of profiles

Profiles3 records

Micropharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Micropharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Micropharma

What does Micropharma do?

Micropharma develops biotherapeutics, diagnostics, and medical devices targeted at metabolic diseases. The company operates as a small private biopharmaceutical and medical device firm headquartered in Montréal, Canada, with 11-50 employees, focused on therapeutic, diagnostic, and device product development for metabolic conditions.

Is Micropharma a public or private company?

Micropharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Micropharma founded?

Micropharma was founded in 2004. It employs 11 to 50 people.

Where is Micropharma based?

Micropharma is headquartered in Montréal, Canada, in the North America region.

Who are Micropharma's main competitors?

Direct peers on record are Seres Therapeutics, Vedanta Biosciences, Novome Biotechnologies, Second Genome, Enterome, Finch Therapeutics and MetaboGen. Emerging players are Kaleido Biosciences and Aprea Therapeutics. BioGaia is listed as a broad incumbent.

Does Micropharma have an API?

No public API is recorded for Micropharma.

What industry is Micropharma in?

Micropharma's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAFAD, Engineered Microbial Therapeutics (synthetic biology, gene circuits), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales